Free Post Earnings Research Report: ResMed’s Revenue and EPS Jumped 13% Y-O-Y

Stock Monitor: Globus Medical Post Earnings Reporting

LONDON, UK / ACCESSWIRE / November 30, 2017 / Active-Investors free earnings report on ResMed Inc. (NYSE: RMD) has freshly been issued to its members, and you can also sign up to view this report at www.active-investors.com/registration-sg/?symbol=RMD. ResMed reported its first quarter fiscal 2018 operating results on October 26, 2017. The maker of medical products for respiratory disorders outperformed top- and bottom-line expectations. Register today and get free access to our complimentary member’s area where many more reports are available:

www.active-investors.com/registration-sg

Active-Investors.comis currently working on the research report for Globus Medical, Inc. (NYSE: GMED), which also belongs to the Healthcare sector as the Company ResMed. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=GMED

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, ResMed most recent news is on our radar and we have decided to include it on our blog post. Today’s free coverage is available at:

www.active-investors.com/registration-sg/?symbol=RMD

Earnings Highlights and Summary

For its quarter ended September 30, 2017, ResMed’s revenue advanced 13% $523.66 million compared to revenue of $465.45 million in Q1 FY17. The Company’s revenue numbers beat analysts’ estimates of $501 million.

During Q1 FY18, ResMed’s gross margin was 58.4%, higher than gross margin of 57.8% in Q1 FY17, with the improvement in gross margin attributed to manufacturing and procurement efficiencies and the prior year’s Astral field safety notification expenses.

For Q1 FY18, ResMed’s selling, general, and administrative (SG&A) expenses were $143.9 million, up 12% on a y-o-y basis, or 10% increase on a constant currency basis. The Company’s SG&A expenses improved to 27.5% of revenue in the reported quarter compared to 27.7% reported in the prior year’s same quarter. The Company’s research and development (R&D) expenses were $37.4 million, or 7.1% of revenue, in Q1 FY18.

During Q1 FY18, ResMed’s income from operations totaled $112.56 million, reflecting a 20% growth compared with income from operations of $94.15 million in Q1 FY17. The Company’s non-GAAP income from operations for the reported quarter was $124.3 million, up 12% on a y-o-y basis.

ResMed’s amortization of acquired intangible assets was $11.8 million during Q1 FY18, consistent on a y-o-y basis. The Company’s stock-based compensation costs incurred during the reported quarter were $11.9 million, consisting of expenses associated with employee equity grants and ResMed’s employee stock purchase plan.

During Q1 FY18, ResMed’s net income advanced 13% to $86.13 million compared to net income of $76.11 million in Q1 FY17. The Company’s non-GAAP net income for the reported quarter totaled $94.1 million, reflecting a 7% increase compared to the prior year’s same quarter.

For Q1 FY18, ResMed’s GAAP diluted earnings per share increased by 11% to $0.60 versus $0.54 in Q1 FY17. The Company’s non-GAAP diluted earnings per share for the reported quarter were 6% higher at $0.66 and ahead of Wall Street’s estimates of $0.65 per share.

ResMed’s Segment Results

During Q1 FY18, revenue in the Americas, excluding Brightree, was $296.6 million, representing growth of 11% on a y-o-y basis. Brightree’s revenue for the reported quarter was $38.1 million, reflecting an increase of 15% compared to the year ago corresponding period. ResMed’s revenue combining Europe, Middle-East, and Africa (EMEA) and Asia/Pacific (APAC) totaled $189.0 million for Q1 FY18, reflecting an increase of 11% on a constant currency basis compared to the same period of the prior year.

In the reported quarter, the Americas device sales grew 8% to $157.9 million on a y-o-y basis. The Company’s Masks and other sales were $138.7 million, reflecting an increase of 13% over the prior-year’s same quarter.

Cash Matters

ResMed’s cash flow from operations for Q1 FY18 was $94.0 million compared to net income in the current quarter of $86.1 million. Capital expenditure for the reported quarter was $16 million. During Q1 FY18, the Company paid $49.7 million in dividends and repaid $60.0 million of its outstanding debt. At September 30, 2017, ResMed’s total assets were $3.5 billion and net equity was $2 billion.

Stock Performance Snapshot

November 29, 2017 – At Wednesday’s closing bell, ResMed’s stock marginally climbed 0.07%, ending the trading session at $85.25.

Volume traded for the day: 406.44 thousand shares.

Stock performance in the last month – up 2.72%; previous three-month period – up 12.79%; past twelve-month period – up 37.26%; and year-to-date – up 37.39%

After yesterday’s close, ResMed’s market cap was at $12.12 billion.

Price to Earnings (P/E) ratio was at 34.54.

The stock has a dividend yield of 1.64%.

The stock is part of the Healthcare sector, categorized under the Medical Appliances & Equipment industry. This sector was up 0.3% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charter-holder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’ re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors

ReleaseID: 483276